LI, ZHEN,李 䂦,ZHU, RUI,朱锐,朱銳,WOODDELL, CHRISTINE I.,伍戴尔 克莉丝丁Ｉ,伍戴爾 克莉絲丁Ｉ,GIVEN, BRUCE D.,齐文 布鲁斯Ｄ,齊文 布魯斯Ｄ,PEI, TAO,裴 涛,裴 濤,LEWIS, DAVID L.,路易士 大卫Ｌ,路易士 大衛Ｌ,ALMEIDA, LAUREN J,阿梅塔 罗伦Ｊ,阿梅塔 羅倫Ｊ,ROZEMA, DA
申请号：
TW106126453
公开号：
TW202018081A
申请日:
2017.08.04
申请国别(地区):
TW
年份:
2020
代理人:
摘要：
Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liverin vivoprovides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.本發明描述用於抑制B型肝炎病毒基因表現之組合物及方法。描述用於抑制B型肝炎病毒基因之表現的RNA干擾(RNAi)藥劑。本文中所揭示之HBV RNAi藥劑可靶向細胞，諸如肝細胞，例如藉由使用結合之靶向配位體。亦描述包含一或多種HBV RNAi藥劑與視情況選用之一或多種其他治療劑的醫藥組合物。將所描述之HBV RNAi藥劑活體內遞送至受感染之肝臟可提供對HBV基因表現之抑制及與HBV感染相關之疾病及病狀的治療。
